X
[{"orgOrder":0,"company":"NodThera","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"NodThera Announces Close of $55 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"NodThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"NodThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NodThera's NT-0796 Meets Primary Endpoint in Inflammation Reversal in Obese Subjects","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by NodThera
Filters
Companies By Therapeutic Area
Details:
NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.
Lead Product(s):
NT-0796
Therapeutic Area: Immunology
Product Name: NT-0796
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 12, 2024
Details:
NT-0796 is a novel chemotype, designed as an orally bioavailable, brain penetrant NLRP3 inhibitor. NT-0796 has completed its Phase 1 study confirming brain penetration with excellent pharmacokinetic (PK) & pharmacodynamic (PD) profiles.
Lead Product(s):
NT-0796
Therapeutic Area: Neurology
Product Name: NT-0796
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 21, 2022
Details:
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Lead Product(s):
NT-0167
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novo Holdings
Deal Size: $55.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
June 03, 2020